• Explore /
  • Poster
  • / Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naïve myelofibrosis.

Abstract Video & Slides Poster

Authors

null

John Mascarenhas

Icahn School of Medicine at Mount Sinai, New York, NY

John Mascarenhas , Keri Renee Maher , Raajit Rampal , Prithviraj Bose , Nikolai Alexandrovich Podoltsev , Junshik Hong , Xulong Wang , Steve Kye , Claire Harrison

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT04562389

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS6594)

DOI

10.1200/JCO.2024.42.16_suppl.TPS6594

Abstract #

TPS6594

Poster Bd #

148b

Abstract Disclosures

Similar Posters

First Author: Haris Ali

First Author: Haris Ali

First Author: Lucia Masarova

First Author: Aaron Thomas Gerds